Avanos Medical, Inc. Announces Third Quarter 2025 Results
Avanos Medical (NYSE: AVNS) reported Q3 2025 results on Nov 5, 2025: total net sales of $177.8 million (+4.3% YoY) and a net loss of $1.4 million (vs. income of $5.9M a year ago). Adjusted net income was $10.1 million and adjusted diluted EPS was $0.22. The company closed the acquisition of Nexus Medical and delivered double‑digit volume growth in its Specialty Nutrition Systems (SNS) segment. Management raised and narrowed full‑year 2025 guidance to $690–700 million revenue and adjusted diluted EPS of $0.85–0.95. The company recorded a $77.0 million goodwill impairment earlier in 2025 and had $70.5 million cash and $102.8 million net debt at Sept 30, 2025.
Avanos Medical (NYSE: AVNS) ha riportato i risultati del terzo trimestre 2025 il 5 novembre 2025: vendite nette totali di $177.8 milioni (+4.3% YoY) e una perdita netta di $1.4 milioni (rispetto a un utile di 5.9 milioni nello stesso periodo dell'anno precedente). L'utile netto rettificato è stato di $10.1 milioni e l'EPS diluito rettificato è stato di $0.22. L'azienda ha chiuso l'acquisizione di Nexus Medical e ha registrato una crescita a doppia cifra del volume nel segmento Specialty Nutrition Systems (SNS). La direzione ha aumentato e affiancato le previsioni per l'intero 2025 a $690–700 milioni di ricavi e a un EPS diluito rettificato di $0.85–0.95. L'azienda ha registrato un impairment del goodwill di $77.0 milioni all'inizio del 2025 e possedeva $70.5 milioni di cassa e $102.8 milioni di debito netto al 30 settembre 2025.
Avanos Medical (NYSE: AVNS) informó los resultados del tercer trimestre de 2025 el 5 de noviembre de 2025: ventas netas totales de $177.8 millones (+4.3% interanual) y una pérdida neta de $1.4 millones (frente a un ingreso de $5.9 millones hace un año). El ingreso neto ajustado fue de $10.1 millones y las ganancias por acción diluida ajustadas fueron de $0.22. La compañía cerró la adquisición de Nexus Medical y registró un crecimiento de dos dígitos en volumen en su segmento de Sistemas de Nutrición Especializada (SNS). La dirección elevó y redujo las previsiones para todo 2025 a $690–700 millones de ingresos y un EPS diluido ajustado de $0.85–0.95. La empresa registró un impairment de goodwill de $77.0 millones a principios de 2025 y tenía $70.5 millones en caja y $102.8 millones de deuda neta al 30 de septiembre de 2025.
Avanos Medical (NYSE: AVNS)는 2025년 11월 5일 3분기 실적을 발표했습니다: 순매출 총액은 $177.8백만이고 YoY +4.3%이며 순손실은 $1.4백만으로 전년 같은 기간의 이익 $5.9백만에서 감소했습니다. 조정 순이익은 $10.1백만이고 조정 희석 주당순이익은 $0.22였습니다. 회사는 Nexus Medical의 인수를 마무리했고 Specialty Nutrition Systems(SNS) 부문에서 두 자릿수의 판매량 성장을 달성했습니다. 경영진은 2025년 전체 가이던스를 매출 $690–700백만과 조정 희석 주당순이익 $0.85–0.95로 상향하고 좁혔습니다. 회사는 2025년 초에 $77.0백만의 영업권 손상을 기록했고 2025년 9월 30일 기준 현금 $70.5백만, 순부채 $102.8백만을 보유했습니다.
Avanos Medical (NYSE: AVNS) a publié les résultats du T3 2025 le 5 novembre 2025 : ventes nettes totales de $177,8 millions (+4,3 % en glissement annuel) et une perte nette de $1,4 million (contre un bénéfice de 5,9 M$ l'année précédente). Le revenu net ajusté était de $10,1 millions et le bénéfice par action dilué ajusté était de $0,22. L'entreprise a finalisé l'acquisition de Nexus Medical et a enregistré une croissance en double chiffres du volume dans le segment des Systèmes de nutrition spécialisée (SNS). La direction a relevé et resserré les prévisions pour l'ensemble de l'année 2025 à $690–700 millions de revenus et un EPS dilué ajusté de $0,85–0,95. L'entreprise a enregistré une impairment du goodwill de $77,0 millions plus tôt en 2025 et disposait de $70,5 millions de liquidités et d'une dette nette de $102,8 millions au 30 septembre 2025.
Avanos Medical (NYSE: AVNS) berichtete am 5. November 2025 über die Ergebnisse des dritten Quartals 2025: Gesamt-Nettoverkäufe von $177.8 Millionen (+4,3 % YoY) und einen Nettoverlust von $1.4 Millionen (im Vergleich zu einem Gewinn von 5,9 Mio. USD im Vorjahr). Das bereinigte Nettoeinkommen betrug $10.1 Millionen und der bereinigte diluierte Gewinn je Aktie war $0.22. Das Unternehmen schloss die Übernahme von Nexus Medical ab und verzeichnete im Segment Specialty Nutrition Systems (SNS) ein zweistelliges Volumenwachstum. Das Management hob die Prognose für das Gesamtjahr 2025 an und verengte sie auf $690–700 Millionen Umsatz und ein bereinigtes diluiertes EPS von $0.85–0.95. Das Unternehmen verzeichnete Anfang 2025 eine Goodwill-Impairment in Höhe von $77.0 Millionen und hielt zum 30. September 2025 Bargeld von $70.5 Millionen sowie Nettenschulden von $102.8 Millionen.
Avanos Medical (NYSE: AVNS) أصدرت نتائج الربع الثالث من عام 2025 في 5 نوفمبر 2025: إجمالي المبيعات الصافية قدره $177.8 مليون (+4.3% على أساس سنوي) وخسارة صافية قدرها $1.4 مليون مقابل دخل قدره 5.9 مليون دولار في العام السابق. بلغ صافي الدخل المعدل $10.1 مليون وربحية السهم المخفف المعدلة $0.22. أتمت الشركة الاستحواذ على Nexus Medical وحققت نموًا مزدوج الأرقام في الحجم ضمن قطاع أنظمة التغذية المتخصصة (SNS). رفعت الإدارة التوجيهات للسنة الكاملة 2025 إلى إيرادات قدرها $690–700 مليون ورقم الربحية المعتدل للسهم المخفف المعدل إلى $0.85–0.95. سجلت الشركة انخفاضًا في goodwill بلغ $77.0 مليون في وقت مبكر من 2025 وكانت لديها $70.5 مليون من النقد و$102.8 مليون من الدين الصافي في 30 سبتمبر 2025.
- SNS net sales $114.0M (+$15.8M vs prior year)
- SNS volume growth 14.0% in Q3 2025
- SNS operating income $23.0M (20% margin)
- Raised 2025 revenue guidance to $690–700M
- Closed acquisition of Nexus Medical adding complementary technology
- Net loss $1.4M in Q3 2025 (vs. $5.9M net income prior year)
- Adjusted EBITDA $20.2M in Q3 2025 (down from $30.6M)
- Goodwill impairment $77.0M recorded in Q2 2025
- Cash balance down to $70.5M from $107.7M at year‑end 2024
Insights
Mixed quarter: modest revenue growth and strong SNS performance offset by a large goodwill charge and lower adjusted profits.
Avanos reported third quarter net sales of
Results include a non-cash goodwill impairment of
Management raised and narrowed full-year revenue guidance to between
- Delivered double-digit growth in Specialty Nutrition Systems segment
- Closed acquisition of Nexus Medical, providing a complementary technology for the Specialty Nutrition Systems segment
- Raising and narrowing top-line guidance and adjusted EPS guidance for the full year
"I am pleased with our third quarter results, both operationally and commercially," said David Pacitti, Avanos' chief executive officer. Pacitti continued, "Avanos delivered double-digit growth in our life-sustaining Specialty Nutrition Systems segment and made continued progress in our opioid-sparing Pain Management and Recovery segment, all while managing through a challenging tariff environment. In addition, we are excited about the recently completed acquisition of Nexus Medical, which adds complementary technology to our Specialty Nutrition Systems offerings and is expected to deliver immediate value in NICU and PICU care."
Third Quarter 2025 Financial Highlights
- Total net sales were
$177.8 million 4.3% increase from the comparable prior year period. - Net loss was
$1.4 million $5.9 million - Adjusted net income was
$10.1 million $16.7 million - Diluted loss per share was
$0.03 $0.12 - Adjusted diluted earnings per share was
$0.22 $0.36 - Adjusted EBITDA was
$20.2 million $30.6 million
Third Quarter of 2025 Operating Results
For the three months ended September 30, 2025, net sales totaled
Operating profit in the third quarter of 2025 was
Third Quarter 2025 Segment Results
Specialty Nutrition Systems
The SNS segment delivered above-market results in the third quarter of 2025, achieving net sales of
Operating income in the SNS segment for the three months ended September 30, 2025 was
Pain Management & Recovery
PM&R segment net sales for the third quarter of 2025 was
First Nine Months of 2025 Operating Results
For the nine months ended September 30, 2025, net sales were
Following a
First Nine Months of 2025 Segment Results
Specialty Nutrition Systems
The SNS segment delivered above-market results in the nine months ended September 30, 2025, achieving net sales of
Operating income in the SNS segment for the nine months ended September 30, 2025 was
Pain Management & Recovery
PM&R segment net sales for the nine months ended September 30, 2025 were
Operating profit in the PM&R segment for the nine months ended September 30, 2025 was
Non-Cash Goodwill Impairment
During the second quarter, due to downward pressure on our market capitalization, we assessed goodwill for impairment and recorded an impairment charge of
Cash Flow and Balance Sheet
We had
Sale of HA Product Line
On July 31, 2025, we announced the divestiture of our HA product line to Channel-Markers Medical, LLC, a privately held company. This transaction aligns with our ongoing transformation, which is focused on advancing our strategic SNS and PM&R segments.
2025 Outlook
We are raising and narrowing our 2025 estimated revenue to between
The guidance on adjusted diluted earnings per share range includes the Company's current estimated impact of tariffs. The estimate assumes that management's mitigation plans will be able to moderate the impact of tariffs, including through cost containment measures, pricing actions where appropriate, supply chain adjustments and reliance on existing international agreements that allow for reduced or duty-free importation of products. Tariff rates continue to fluctuate, and if the final tariffs are higher than we anticipate, or if we are unable to successfully mitigate the impact of tariffs, the adverse effect on the Company's business, financial condition, results of operations, cash flows and guidance could be material. The ultimate impact from any tariffs remains uncertain and will depend on various factors, including the level of our imports from
Non-GAAP Financial Measures
This press release and the accompanying tables include the following financial measures that have not been calculated in accordance with accounting principles generally accepted in the
- Adjusted gross and operating income;
- Adjusted income before taxes;
- Adjusted effective tax rate;
- Adjusted net income;
- Adjusted diluted earnings per share;
- Adjusted selling, general and administrative expenses;
- Adjusted EBITDA; and
- Free cash flow.
These non-GAAP financial measures exclude the following items, as applicable, for the relevant time periods as indicated in the accompanying non-GAAP reconciliations to the comparable GAAP financial measures:
- Certain acquisition and integration charges related to acquisitions;
- Expenses associated with restructuring and transformation activities, including the divestiture of the Company's respiratory health business;
- Expenses associated with European Union Medical Device Regulation ("EU MDR") compliance;
- The amortization of intangible assets associated with business acquisitions;
- Impairments of intangibles or goodwill;
- The tax effects of certain adjusting items; and
- The positive or negative effect of changes in currency exchange rates during the year.
The Company provides these non-GAAP financial measures as supplemental information to its GAAP financial measures. Management and the Company's board of directors use net sales on a constant currency basis, adjusted net income, adjusted diluted earnings per share, adjusted operating income, adjusted EBITDA, and free cash flow to: (a) evaluate the Company's historical and prospective financial performance and its performance relative to its competitors, (b) allocate resources and (c) measure the operational performance of the Company's business units and their managers. Management also believes that the use of an adjusted effective tax rate provides improved insight into the tax effects of the Company's ongoing business operations.
Additionally, the compensation committee of the Company's board of directors will use certain of the non-GAAP financial measures when setting and assessing achievement of incentive compensation goals. These goals are based, in part, on the Company's net sales on a constant currency basis and adjusted EBITDA, which will be determined by excluding certain items that are used in calculating these non-GAAP financial measures.
Our competitors may define these non-GAAP financial measures differently, and as a result, our measure of these non-GAAP financial measures may not be directly comparable to those of other companies. Items excluded from these non-GAAP financial measures are significant components in understanding and assessing financial performance. These non-GAAP financial measures are supplemental measures of operating performance that do not represent, and should not be considered in isolation or as an alternative to, or substitute for, the financial statement data presented in the Company's consolidated financial statements as indicators of financial performance. These non-GAAP financial measures have limitations as analytical tools, and should not be considered in isolation, or as a substitute for analysis of the Company's results as reported under GAAP. We compensate for these limitations by relying primarily on our GAAP results and using these non-GAAP financial measures as supplemental information.
Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the attached financial tables.
Conference Call Webcast
Avanos Medical, Inc. will host a conference call today at 9 a.m. ET. To instantly join the conference by phone, use the following link to register close to the start time: https://emportal.ink/3OBYJOf. After registering, the system will call you and automatically connect you to the conference call. Alternatively, you may join the call by dialing 1-646-357-8785 or 1-800-836-8184 and you will be connected to the call by an operator. A simultaneous webcast of the call and presentation will be accessible via the Investors section of the Avanos Medical website, https://avanos.investorroom.com. A replay of the call will be available within two hours of the end of the call and will be available for one week. Alternatively, you may dial 1-646-517-4150 or 1-888-660-6345 in
About Avanos Medical, Inc.
Avanos Medical (NYSE: AVNS) is a medical technology company focused on delivering clinically superior solutions that will help patients get back to the things that matter. Headquartered in
Forward-Looking Statements
This press release contains information that includes or is based on "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as "may," "believe," "will," "expect," "project," "estimate," "anticipate," "plan" or "continue" and similar expressions. Forward-looking statements are based on the current plans and expectations of management and are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; shortage in drugs used in our Surgical Pain and Recovery products or other disruptions in our supply chain; the ongoing regional conflicts between
Additional information concerning these and other factors that may impact future results is contained in our filings with the
|
AVANOS MEDICAL, INC. |
|||||||
|
CONDENSED CONSOLIDATED INCOME STATEMENTS |
|||||||
|
(unaudited) |
|||||||
|
(in millions, except per share amounts) |
|||||||
|
|
|||||||
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
||||
|
|
2025 |
|
2024 |
|
2025 |
|
2024 |
|
Net Sales |
$ 177.8 |
|
$ 170.4 |
|
$ 520.3 |
|
508.2 |
|
Cost of products sold |
91.8 |
|
77.5 |
|
252.4 |
|
224.9 |
|
Gross Profit |
86.0 |
|
92.9 |
|
267.9 |
|
283.3 |
|
Research and development expenses |
6.0 |
|
7.2 |
|
17.2 |
|
20.5 |
|
Selling and general expenses |
77.6 |
|
74.3 |
|
236.8 |
|
238.8 |
|
Goodwill impairment |
— |
|
— |
|
77.0 |
|
— |
|
Other expense (income), net |
2.3 |
|
(0.6) |
|
1.0 |
|
1.7 |
|
Operating Income (Loss) |
0.1 |
|
12.0 |
|
(64.1) |
|
22.3 |
|
Interest income |
0.5 |
|
0.7 |
|
2.6 |
|
4.3 |
|
Interest expense |
(1.8) |
|
(3.2) |
|
(5.9) |
|
(9.4) |
|
(Loss) Income Before Income Taxes |
(1.2) |
|
9.5 |
|
(67.4) |
|
17.2 |
|
Income tax provision |
(0.2) |
|
(3.6) |
|
(4.2) |
|
(6.5) |
|
(Loss) Income from Continuing Operations |
(1.4) |
|
5.9 |
|
(71.6) |
|
10.7 |
|
Loss from discontinued operations, net of tax |
— |
|
(1.6) |
|
— |
|
(5.5) |
|
Net (Loss) Income |
$ (1.4) |
|
$ 4.3 |
|
$ (71.6) |
|
$ 5.2 |
|
|
|
|
|
|
|
|
|
|
Interest expense, net |
$ 1.3 |
|
$ 2.5 |
|
$ 3.3 |
|
$ 5.1 |
|
Income tax provision |
0.2 |
|
3.0 |
|
4.2 |
|
4.5 |
|
Depreciation and amortization |
9.4 |
|
11.7 |
|
29.0 |
|
34.4 |
|
EBITDA |
$ 9.5 |
|
$ 21.5 |
|
$ (35.1) |
|
$ 49.2 |
|
|
|
|
|
|
|
|
|
|
(Loss) Earnings Per Share |
|
|
|
|
|
|
|
|
Basic |
|
|
|
|
|
|
|
|
Continuing operations |
$ (0.03) |
|
$ 0.13 |
|
$ (1.55) |
|
$ 0.23 |
|
Discontinued operations |
— |
|
(0.03) |
|
— |
|
(0.12) |
|
Basic (Loss) Earnings Per Share |
$ (0.03) |
|
$ 0.10 |
|
$ (1.55) |
|
$ 0.11 |
|
|
|
|
|
|
|
|
|
|
Diluted |
|
|
|
|
|
|
|
|
Continuing operations |
$ (0.03) |
|
$ 0.12 |
|
$ (1.55) |
|
$ 0.23 |
|
Discontinued operations |
— |
|
(0.03) |
|
— |
|
(0.12) |
|
Diluted (Loss) Earnings Per Share |
$ (0.03) |
|
$ 0.09 |
|
$ (1.55) |
|
$ 0.11 |
|
|
|
|
|
|
|
|
|
|
Common Shares Outstanding |
|
|
|
|
|
|
|
|
Basic |
46.4 |
|
46.0 |
|
46.3 |
|
46.0 |
|
Diluted |
46.4 |
|
46.6 |
|
46.3 |
|
46.5 |
|
AVANOS MEDICAL, INC. |
|||||||
|
Discontinued Operations Summary |
|||||||
|
(unaudited) |
|||||||
|
(in millions, except per share amounts) |
|||||||
|
|
|||||||
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
||||
|
|
2025 |
|
2024 |
|
2025 |
|
2024 |
|
Net Sales |
$ — |
|
$ 10.5 |
|
$ — |
|
$ 41.0 |
|
Cost of products sold |
— |
|
15.9 |
|
— |
|
47.4 |
|
Gross Profit |
— |
|
(5.4) |
|
— |
|
(6.4) |
|
Other (income) expense, net |
— |
|
(3.2) |
|
— |
|
1.1 |
|
Loss from discontinued operations before income |
— |
|
(2.2) |
|
— |
|
(7.5) |
|
Income tax benefit from discontinued operations |
— |
|
0.6 |
|
— |
|
2.0 |
|
Loss from discontinued operations, net of tax |
$ — |
|
$ (1.6) |
|
$ — |
|
$ (5.5) |
|
|
|
|
|
|
|
|
|
|
Loss Per Share |
|
|
|
|
|
|
|
|
Basic |
$ — |
|
$ (0.03) |
|
$ — |
|
$ (0.12) |
|
Diluted |
$ — |
|
$ (0.03) |
|
$ — |
|
$ (0.12) |
|
AVANOS MEDICAL, INC. |
|||||||
|
NON-GAAP RECONCILIATIONS |
|||||||
|
(unaudited) |
|||||||
|
(in millions) |
|||||||
|
|
|||||||
|
|
Gross Profit |
||||||
|
|
Three Months |
|
Three Months Ended September 30, 2024 |
||||
|
|
|
Continuing
|
|
Discontinued
|
|
Total |
|
|
As reported |
$ 86.0 |
|
$ 92.9 |
|
$ (5.4) |
|
87.5 |
|
Restructuring and transformation charges |
— |
|
0.7 |
|
— |
|
0.7 |
|
Post-RH Divestiture transition charges |
— |
|
0.6 |
|
— |
|
0.6 |
|
Post-RH Divestiture restructuring |
5.9 |
|
0.8 |
|
— |
|
0.8 |
|
EU MDR Compliance |
— |
|
0.2 |
|
— |
|
0.2 |
|
Intangibles amortization |
2.0 |
|
3.7 |
|
— |
|
3.7 |
|
As adjusted non-GAAP |
$ 93.9 |
|
$ 98.9 |
|
$ (5.4) |
|
$ 93.5 |
|
Gross profit margin, as reported |
48.4 % |
|
54.5 % |
|
(51.4) % |
|
48.4 % |
|
Gross profit margin, as adjusted |
52.8 % |
|
58.0 % |
|
(51.4) % |
|
51.7 % |
|
|
|||||||
|
|
Gross Profit |
||||||
|
|
Nine Months |
|
Nine Months Ended September 30, 2024 |
||||
|
|
|
Continuing
|
|
Discontinued
|
|
Total |
|
|
As reported |
$ 267.9 |
|
$ 283.3 |
|
$ (6.4) |
|
$ 276.9 |
|
Acquisition and integration-related charges |
— |
|
0.1 |
|
— |
|
0.1 |
|
Restructuring and transformation charges |
— |
|
1.7 |
|
— |
|
1.7 |
|
Post-RH Divestiture transition charges |
— |
|
1.4 |
|
— |
|
1.4 |
|
Post-RH Divestiture restructuring |
10.5 |
|
3.0 |
|
— |
|
3.0 |
|
EU MDR Compliance |
— |
|
0.2 |
|
— |
|
0.2 |
|
Intangibles amortization |
7.9 |
|
10.7 |
|
— |
|
10.7 |
|
As adjusted non-GAAP |
$ 286.3 |
|
$ 300.4 |
|
$ (6.4) |
|
$ 294.0 |
|
Gross profit margin, as reported |
51.5 % |
|
55.7 % |
|
(15.6) % |
|
50.4 % |
|
Gross profit margin, as adjusted |
55.0 % |
|
59.1 % |
|
(15.6) % |
|
53.5 % |
|
AVANOS MEDICAL, INC. |
|||||||
|
NON-GAAP RECONCILIATIONS |
|||||||
|
(unaudited) |
|||||||
|
(in millions) |
|||||||
|
|
|||||||
|
|
Operating Income (Loss) |
||||||
|
|
Three Months |
|
Three Months Ended September 30, 2024 |
||||
|
|
|
Continuing
|
|
Discontinued
|
|
Total |
|
|
As reported |
$ 0.1 |
|
$ 12.0 |
|
$ (2.2) |
|
$ 9.8 |
|
Acquisition and integration-related charges |
0.4 |
|
1.6 |
|
— |
|
1.6 |
|
Restructuring and transformation charges |
— |
|
0.7 |
|
— |
|
0.7 |
|
Post-RH Divestiture transition charges |
— |
|
0.7 |
|
— |
|
0.7 |
|
Post-RH Divestiture restructuring |
10.3 |
|
2.3 |
|
— |
|
2.3 |
|
EU MDR Compliance |
— |
|
1.6 |
|
— |
|
1.6 |
|
Intangibles amortization |
4.4 |
|
6.4 |
|
— |
|
6.4 |
|
As adjusted non-GAAP |
$ 15.2 |
|
$ 25.3 |
|
$ (2.2) |
|
$ 23.1 |
|
|
|||||||
|
|
Operating Income (Loss) |
||||||
|
|
Nine Months |
|
Nine Months Ended September 30, 2024 |
||||
|
|
|
Continuing
|
|
Discontinued
|
|
Total |
|
|
As reported |
$ (64.1) |
|
$ 22.3 |
|
$ (7.5) |
|
$ 14.8 |
|
Acquisition and integration-related charges |
0.4 |
|
4.1 |
|
— |
|
4.1 |
|
Restructuring and transformation charges |
— |
|
5.2 |
|
— |
|
5.2 |
|
Post-RH Divestiture transition charges |
— |
|
2.2 |
|
— |
|
2.2 |
|
Post-RH Divestiture restructuring |
17.9 |
|
6.4 |
|
— |
|
6.4 |
|
Goodwill impairment |
77.0 |
|
— |
|
— |
|
— |
|
EU MDR Compliance |
— |
|
4.4 |
|
— |
|
4.4 |
|
Litigation and legal |
(1.4) |
|
— |
|
— |
|
— |
|
Intangibles amortization |
14.7 |
|
18.8 |
|
— |
|
18.8 |
|
As adjusted non-GAAP |
$ 44.5 |
|
$ 63.4 |
|
$ (7.5) |
|
$ 55.9 |
|
|
|
|
|
|
|
|
|
|
AVANOS MEDICAL, INC. |
|||||||
|
NON-GAAP RECONCILIATIONS |
|||||||
|
(unaudited) |
|||||||
|
(in millions) |
|||||||
|
|
|||||||
|
|
Income (Loss) Before Taxes |
||||||
|
|
Three Months |
|
Three Months Ended September 30, 2024 |
||||
|
|
|
Continuing
|
|
Discontinued
|
|
Total |
|
|
As reported |
$ (1.2) |
|
$ 9.5 |
|
$ (2.2) |
|
$ 7.3 |
|
Acquisition and integration-related charges |
0.4 |
|
1.6 |
|
— |
|
1.6 |
|
Restructuring and transformation charges |
— |
|
0.7 |
|
— |
|
0.7 |
|
Post-RH Divestiture transition charges |
— |
|
0.7 |
|
— |
|
0.7 |
|
Post-RH Divestiture restructuring |
10.3 |
|
2.3 |
|
— |
|
2.3 |
|
EU MDR Compliance |
— |
|
1.6 |
|
— |
|
1.6 |
|
Intangibles amortization |
4.4 |
|
6.4 |
|
— |
|
6.4 |
|
As adjusted non-GAAP |
$ 13.9 |
|
$ 22.8 |
|
$ (2.2) |
|
$ 20.6 |
|
|
|||||||
|
|
Income (Loss) Before Taxes |
||||||
|
|
Nine Months |
|
Nine Months Ended September 30, 2024 |
||||
|
|
|
Continuing
|
|
Discontinued
|
|
Total |
|
|
As reported |
$ (67.4) |
|
$ 17.2 |
|
$ (7.5) |
|
$ 9.7 |
|
Acquisition and integration-related charges |
0.4 |
|
4.1 |
|
— |
|
4.1 |
|
Restructuring and transformation charges |
— |
|
5.2 |
|
— |
|
5.2 |
|
Post-RH Divestiture transition charges |
— |
|
2.2 |
|
— |
|
2.2 |
|
Post-RH Divestiture restructuring |
17.9 |
|
6.4 |
|
— |
|
6.4 |
|
Goodwill impairment |
77.0 |
|
— |
|
— |
|
— |
|
EU MDR Compliance |
— |
|
4.4 |
|
— |
|
4.4 |
|
Litigation and legal |
(1.4) |
|
— |
|
— |
|
— |
|
Intangibles amortization |
14.7 |
|
18.8 |
|
— |
|
18.8 |
|
As adjusted non-GAAP |
$ 41.2 |
|
$ 58.3 |
|
$ (7.5) |
|
$ 50.8 |
|
AVANOS MEDICAL, INC. |
|||||||
|
NON-GAAP RECONCILIATIONS |
|||||||
|
(unaudited) |
|||||||
|
(in millions) |
|||||||
|
|
|||||||
|
|
Tax (Provision) Benefit |
||||||
|
|
Three Months |
|
Three Months Ended September 30, 2024 |
||||
|
|
|
Continuing
|
|
Discontinued
|
|
Total |
|
|
As reported |
$ (0.2) |
|
$ (3.6) |
|
$ 0.6 |
|
$ (3.0) |
|
Tax effects of adjusting items |
(3.6) |
|
(2.5) |
|
— |
|
(2.5) |
|
As adjusted non-GAAP |
$ (3.8) |
|
$ (6.1) |
|
$ 0.6 |
|
$ (5.5) |
|
Effective tax rate, as reported |
(16.7) % |
|
37.9 % |
|
27.3 % |
|
41.1 % |
|
Effective tax rate, as adjusted |
27.3 % |
|
26.8 % |
|
27.3 % |
|
26.7 % |
|
|
|||||||
|
|
Tax (Provision) Benefit |
||||||
|
|
Nine Months |
|
Nine Months Ended September 30, 2024 |
||||
|
|
|
Continuing
|
|
Discontinued
|
|
Total |
|
|
As reported |
$ (4.2) |
|
$ (6.5) |
|
$ 2.0 |
|
$ (4.5) |
|
Tax effects of adjusting items |
(7.0) |
|
(9.2) |
|
— |
|
(9.2) |
|
As adjusted non-GAAP |
$ (11.2) |
|
$ (15.7) |
|
$ 2.0 |
|
$ (13.7) |
|
Effective tax rate, as reported |
(6.2) % |
|
37.8 % |
|
26.7 % |
|
46.4 % |
|
Effective tax rate, as adjusted |
27.2 % |
|
26.9 % |
|
26.7 % |
|
27.0 % |
|
AVANOS MEDICAL, INC. |
|||||||
|
NON-GAAP RECONCILIATIONS |
|||||||
|
(unaudited) |
|||||||
|
(in millions except per share amounts) |
|||||||
|
|
|||||||
|
|
Net Income (Loss) |
||||||
|
|
Three Months |
|
Three Months Ended September 30, 2024 |
||||
|
|
|
Continuing
|
|
Discontinued
|
|
Total |
|
|
As reported |
$ (1.4) |
|
$ 5.9 |
|
$ (1.6) |
|
$ 4.3 |
|
Acquisition and integration-related charges |
0.4 |
|
1.6 |
|
— |
|
1.6 |
|
Restructuring and transformation charges |
— |
|
0.7 |
|
— |
|
0.7 |
|
Post-RH Divestiture transition charges |
— |
|
0.7 |
|
— |
|
0.7 |
|
Post-RH Divestiture restructuring |
10.3 |
|
2.3 |
|
— |
|
2.3 |
|
EU MDR Compliance |
— |
|
1.6 |
|
— |
|
1.6 |
|
Intangibles amortization |
4.4 |
|
6.4 |
|
— |
|
6.4 |
|
Tax effects of adjusting items |
(3.6) |
|
(2.5) |
|
— |
|
(2.5) |
|
As adjusted non-GAAP |
$ 10.1 |
|
$ 16.7 |
|
$ (1.6) |
|
$ 15.1 |
|
Diluted (loss) earnings per share, as reported |
$ (0.03) |
|
$ 0.12 |
|
$ (0.03) |
|
$ 0.09 |
|
Diluted earnings (loss) per share, as adjusted |
$ 0.22 |
|
$ 0.36 |
|
$ (0.03) |
|
$ 0.33 |
|
|
|||||||
|
|
Net Income (Loss) |
||||||
|
|
Nine Months |
|
Nine Months Ended September 30, 2024 |
||||
|
|
|
Continuing
|
|
Discontinued
|
|
Total |
|
|
As reported |
$ (71.6) |
|
$ 10.7 |
|
$ (5.5) |
|
$ 5.2 |
|
Acquisition and integration-related charges |
0.4 |
|
4.1 |
|
— |
|
4.1 |
|
Restructuring and transformation charges |
— |
|
5.2 |
|
— |
|
5.2 |
|
Post-RH Divestiture transition charges |
— |
|
2.2 |
|
— |
|
2.2 |
|
Post-RH Divestiture restructuring |
17.9 |
|
6.4 |
|
— |
|
6.4 |
|
Goodwill impairment |
77.0 |
|
— |
|
— |
|
— |
|
EU MDR Compliance |
— |
|
4.4 |
|
— |
|
4.4 |
|
Litigation and legal |
(1.4) |
|
— |
|
— |
|
— |
|
Intangibles amortization |
14.7 |
|
18.8 |
|
— |
|
18.8 |
|
Tax effects of adjusting items |
(7.0) |
|
(9.2) |
|
— |
|
(9.2) |
|
As adjusted non-GAAP |
$ 30.0 |
|
$ 42.6 |
|
$ (5.5) |
|
$ 37.1 |
|
Diluted (loss) earnings per share, as reported |
$ (1.55) |
|
$ 0.23 |
|
$ (0.12) |
|
$ 0.11 |
|
Diluted earnings (loss) per share, as adjusted |
$ 0.65 |
|
$ 0.92 |
|
$ (0.12) |
|
$ 0.80 |
|
AVANOS MEDICAL, INC. |
|||||||
|
NON-GAAP RECONCILIATIONS |
|||||||
|
(unaudited) |
|||||||
|
(in millions except per share amounts) |
|||||||
|
|
|||||||
|
|
Selling, General and Administrative Expenses |
||||||
|
|
Three Months |
|
Three Months Ended September 30, 2024 |
||||
|
|
|
Continuing
|
|
Discontinued
|
|
Total |
|
|
As reported |
$ 77.6 |
|
$ 74.3 |
|
$ — |
|
$ 74.3 |
|
Acquisition and integration-related charges |
(0.4) |
|
(0.7) |
|
— |
|
(0.7) |
|
Post-RH Divestiture transition charges |
— |
|
(0.1) |
|
— |
|
(0.1) |
|
Post-RH Divestiture restructuring |
(2.7) |
|
(1.5) |
|
— |
|
(1.5) |
|
EU MDR Compliance |
— |
|
(1.4) |
|
— |
|
(1.4) |
|
Intangibles amortization |
(2.4) |
|
(2.7) |
|
— |
|
(2.7) |
|
As adjusted non-GAAP |
$ 72.1 |
|
$ 67.9 |
|
$ — |
|
$ 67.9 |
|
SG&A as a percentage of revenue, as reported |
43.6 % |
|
43.6 % |
|
— % |
|
41.1 % |
|
SG&A as a percentage of revenue, as adjusted |
40.6 % |
|
39.8 % |
|
— % |
|
37.5 % |
|
|
|||||||
|
|
Selling, General and Administrative Expenses |
||||||
|
|
Nine Months |
|
Nine Months Ended September 30, 2024 |
||||
|
|
|
Continuing
|
|
Discontinued
|
|
Total |
|
|
As reported |
$ 236.8 |
|
$ 238.8 |
|
$ — |
|
$ 238.8 |
|
Acquisition and integration-related charges |
(0.4) |
|
(1.3) |
|
— |
|
(1.3) |
|
Restructuring and transformation charges |
— |
|
(3.4) |
|
— |
|
(3.4) |
|
Post-RH Divestiture transition charges |
— |
|
(0.6) |
|
— |
|
(0.6) |
|
Post-RH Divestiture restructuring |
(5.7) |
|
(3.4) |
|
— |
|
(3.4) |
|
EU MDR Compliance |
— |
|
(4.2) |
|
— |
|
(4.2) |
|
Intangibles amortization |
(6.8) |
|
(8.1) |
|
— |
|
(8.1) |
|
As adjusted non-GAAP |
$ 223.9 |
|
$ 217.8 |
|
$ — |
|
$ 217.8 |
|
SG&A as a percentage of revenue, as reported |
45.5 % |
|
47.0 % |
|
— % |
|
43.5 % |
|
SG&A as a percentage of revenue, as adjusted |
43.0 % |
|
42.9 % |
|
— % |
|
39.7 % |
|
AVANOS MEDICAL, INC. |
|||||||
|
NON-GAAP RECONCILIATIONS |
|||||||
|
(unaudited) |
|||||||
|
(in millions) |
|||||||
|
|
|||||||
|
|
EBITDA |
||||||
|
|
Three Months |
|
Three Months Ended September 30, 2024 |
||||
|
|
|
Continuing
|
|
Discontinued
|
|
Total |
|
|
Net (loss) income |
$ (1.4) |
|
$ 5.9 |
|
$ (1.6) |
|
$ 4.3 |
|
Interest expense, net |
1.3 |
|
2.5 |
|
— |
|
2.5 |
|
Income tax provision (benefit) |
0.2 |
|
3.6 |
|
(0.6) |
|
3.0 |
|
Depreciation |
5.0 |
|
5.3 |
|
— |
|
5.3 |
|
Amortization |
4.4 |
|
6.4 |
|
— |
|
6.4 |
|
EBITDA |
9.5 |
|
23.7 |
|
(2.2) |
|
21.5 |
|
Acquisition and integration-related charges |
0.4 |
|
1.6 |
|
— |
|
1.6 |
|
Restructuring and transformation charges |
— |
|
0.7 |
|
— |
|
0.7 |
|
Post-RH Divestiture transition charges |
— |
|
0.7 |
|
— |
|
0.7 |
|
Post-RH Divestiture restructuring |
10.3 |
|
2.3 |
|
— |
|
2.3 |
|
EU MDR Compliance |
— |
|
1.6 |
|
— |
|
1.6 |
|
Adjusted EBITDA |
$ 20.2 |
|
$ 30.6 |
|
$ (2.2) |
|
$ 28.4 |
|
|
|||||||
|
|
EBITDA |
||||||
|
|
Nine Months |
|
Nine Months Ended September 30, 2024 |
||||
|
|
|
Continuing
|
|
Discontinued
|
|
Total |
|
|
Net (loss) income |
$ (71.6) |
|
$ 10.7 |
|
$ (5.5) |
|
$ 5.2 |
|
Interest expense, net |
3.3 |
|
5.1 |
|
— |
|
5.1 |
|
Income tax provision (benefit) |
4.2 |
|
6.5 |
|
(2.0) |
|
4.5 |
|
Depreciation |
14.3 |
|
15.6 |
|
— |
|
15.6 |
|
Amortization |
14.7 |
|
18.8 |
|
— |
|
18.8 |
|
EBITDA |
(35.1) |
|
56.7 |
|
(7.5) |
|
49.2 |
|
Acquisition and integration-related charges |
0.4 |
|
4.1 |
|
— |
|
4.1 |
|
Restructuring and transformation charges |
— |
|
5.2 |
|
— |
|
5.2 |
|
Post-RH Divestiture transition charges |
— |
|
2.2 |
|
— |
|
2.2 |
|
Post-RH Divestiture restructuring |
17.9 |
|
6.4 |
|
— |
|
6.4 |
|
Goodwill impairment |
77.0 |
|
— |
|
— |
|
— |
|
EU MDR Compliance |
— |
|
4.4 |
|
— |
|
4.4 |
|
Litigation and legal |
(1.4) |
|
— |
|
— |
|
— |
|
Adjusted EBITDA |
$ 58.8 |
|
$ 79.0 |
|
$ (7.5) |
|
$ 71.5 |
|
AVANOS MEDICAL, INC. |
|||||||
|
NON-GAAP RECONCILIATIONS |
|||||||
|
(unaudited) |
|||||||
|
(in millions except per share amounts) |
|||||||
|
|
|||||||
|
|
Free Cash Flow |
||||||
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
||||
|
|
2025 |
|
2024 |
|
2025 |
|
2024 |
|
Cash provided by operating activities |
$ 14.0 |
|
$ 23.0 |
|
$ 46.5 |
|
$ 42.8 |
|
Capital expenditures |
(7.0) |
|
(3.0) |
|
(24.7) |
|
(13.0) |
|
Free Cash Flow |
$ 7.0 |
|
$ 20.0 |
|
$ 21.8 |
|
$ 29.8 |
|
2025 OUTLOOK |
|||
|
|
|||
|
|
Estimated Range |
||
|
Diluted earnings per share (GAAP) |
$ 0.43 |
to |
$ 0.56 |
|
Intangibles amortization |
0.25 |
to |
0.24 |
|
Post RH-Divestiture restructuring charges |
0.12 |
to |
0.10 |
|
Other |
0.05 |
to |
0.05 |
|
Adjusted diluted earnings per share (non-GAAP) |
$ 0.85 |
to |
$ 0.95 |
|
|
|
|
|
|
AVANOS MEDICAL, INC. |
|||
|
CONDENSED CONSOLIDATED BALANCE SHEETS |
|||
|
(unaudited) |
|||
|
(in millions) |
|||
|
|
|||
|
|
September 30,
|
|
December 31,
|
|
ASSETS |
|
|
|
|
Current Assets |
|
|
|
|
Cash and cash equivalents |
$ 70.5 |
|
$ 107.7 |
|
Accounts receivable, net |
111.5 |
|
132.8 |
|
Inventories |
150.6 |
|
138.8 |
|
Prepaid and other current assets |
18.8 |
|
14.1 |
|
Total Current Assets |
351.4 |
|
393.4 |
|
Property, Plant and Equipment, net |
115.4 |
|
110.7 |
|
Operating Lease Right-of-Use Assets |
29.9 |
|
34.1 |
|
Goodwill |
394.4 |
|
455.6 |
|
Other Intangible Assets, net |
122.0 |
|
112.3 |
|
Deferred Tax Assets |
25.3 |
|
24.9 |
|
Other Assets |
29.3 |
|
23.2 |
|
TOTAL ASSETS |
$ 1,067.7 |
|
$ 1,154.2 |
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
Current Liabilities |
|
|
|
|
Current portion of long-term debt |
$ 9.4 |
|
$ 9.4 |
|
Current portion of operating lease liabilities |
9.5 |
|
10.9 |
|
Trade accounts payable |
54.2 |
|
54.3 |
|
Accrued expenses |
74.8 |
|
91.3 |
|
Total Current Liabilities |
147.9 |
|
165.9 |
|
Long-Term Debt |
93.4 |
|
125.3 |
|
Operating Lease Liabilities |
21.4 |
|
24.6 |
|
Deferred Tax Liabilities |
6.3 |
|
5.5 |
|
Other Long-Term Liabilities |
20.7 |
|
4.4 |
|
TOTAL LIABILITIES |
289.7 |
|
325.7 |
|
Stockholders' Equity |
778.0 |
|
828.5 |
|
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |
$ 1,067.7 |
|
$ 1,154.2 |
|
AVANOS MEDICAL, INC. |
|||||||
|
CONDENSED CONSOLIDATED CASH FLOW STATEMENTS |
|||||||
|
(unaudited) |
|||||||
|
(in millions) |
|||||||
|
|
|||||||
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
||||
|
|
2025 |
|
2024 |
|
2025 |
|
2024 |
|
Operating Activities |
|
|
|
|
|
|
|
|
Net (loss) income |
$ (1.4) |
|
$ 4.3 |
|
$ (71.6) |
|
$ 5.2 |
|
Depreciation and amortization |
9.4 |
|
11.7 |
|
29.0 |
|
34.4 |
|
Goodwill impairment |
— |
|
— |
|
77.0 |
|
— |
|
Loss on asset dispositions |
5.4 |
|
0.1 |
|
5.7 |
|
0.4 |
|
Changes in operating assets and liabilities, net of |
(2.9) |
|
3.7 |
|
(4.3) |
|
(10.0) |
|
Deferred income taxes and other |
3.5 |
|
3.2 |
|
10.7 |
|
12.8 |
|
Cash Provided by Operating Activities |
14.0 |
|
23.0 |
|
46.5 |
|
42.8 |
|
Investing Activities |
|
|
|
|
|
|
|
|
Capital expenditures |
(7.0) |
|
(3.0) |
|
(24.7) |
|
(13.0) |
|
Proceeds from the sale of assets |
4.0 |
|
— |
|
4.0 |
|
— |
|
Proceeds from RH Divestiture post-closing |
— |
|
— |
|
— |
|
2.1 |
|
Acquisition of assets and investments in businesses |
(28.3) |
|
— |
|
(28.3) |
|
— |
|
Investment in non-affiliates |
(0.2) |
|
(9.0) |
|
(4.8) |
|
(9.0) |
|
Cash Used in Investing Activities |
(31.5) |
|
(12.0) |
|
(53.8) |
|
(19.9) |
|
Financing Activities |
|
|
|
|
|
|
|
|
Secured debt repayments |
(2.3) |
|
(3.2) |
|
(7.0) |
|
(6.3) |
|
Revolving credit facility proceeds |
— |
|
— |
|
— |
|
20.0 |
|
Revolving credit facility repayments |
— |
|
(10.0) |
|
(25.0) |
|
(20.0) |
|
Purchases of treasury stock |
— |
|
(0.1) |
|
(3.0) |
|
(12.7) |
|
Proceeds from the exercise of stock options |
0.3 |
|
0.6 |
|
0.7 |
|
1.1 |
|
Payment of contingent consideration liabilities |
— |
|
(3.3) |
|
— |
|
(3.8) |
|
Cash Used in Financing Activities |
(2.0) |
|
(16.0) |
|
(34.3) |
|
(21.7) |
|
Effect of Exchange Rate Changes on Cash and Cash |
(0.3) |
|
1.8 |
|
4.4 |
|
0.1 |
|
(Decrease) Increase in Cash and Cash Equivalents |
(19.8) |
|
(3.2) |
|
(37.2) |
|
1.3 |
|
Cash and Cash Equivalents - Beginning of Period |
90.3 |
|
92.2 |
|
107.7 |
|
87.7 |
|
Cash and Cash Equivalents - End of Period |
$ 70.5 |
|
$ 89.0 |
|
$ 70.5 |
|
$ 89.0 |
|
AVANOS MEDICAL, INC. |
|||||||||||
|
SELECTED BUSINESS SEGMENT DATA |
|||||||||||
|
(unaudited) |
|||||||||||
|
(in millions) |
|||||||||||
|
|
|||||||||||
|
|
Three Months Ended |
|
|
|
Nine Months Ended September |
|
|
||||
|
|
2025 |
|
2024 |
|
Change |
|
2025 |
|
2024 |
|
Change |
|
Specialty Nutrition Systems: |
|
|
|
|
|
|
|
|
|
|
|
|
Enteral feeding |
$ 82.7 |
|
$ 72.0 |
|
14.9 % |
|
$ 231.7 |
|
$ 214.7 |
|
7.9 % |
|
Neonate solutions |
31.3 |
|
26.2 |
|
19.5 % |
|
86.1 |
|
75.8 |
|
13.6 % |
|
Total Specialty Nutrition Systems |
114.0 |
|
98.2 |
|
16.1 % |
|
317.8 |
|
290.5 |
|
9.4 % |
|
Pain Management & Recovery: |
|
|
|
|
|
|
|
|
|
|
|
|
Surgical pain and recovery |
24.4 |
|
26.5 |
|
(7.9) % |
|
74.1 |
|
81.3 |
|
(8.9) % |
|
Radiofrequency Ablation |
34.6 |
|
31.3 |
|
10.5 % |
|
102.1 |
|
92.1 |
|
10.9 % |
|
Total Pain Management & Recovery |
59.0 |
|
57.8 |
|
2.1 % |
|
176.2 |
|
173.4 |
|
1.6 % |
|
Corporate and Other |
4.8 |
|
14.4 |
|
(66.7) % |
|
26.3 |
|
44.3 |
|
(40.6) % |
|
Total Net Sales |
$ 177.8 |
|
$ 170.4 |
|
4.3 % |
|
$ 520.3 |
|
$ 508.2 |
|
2.4 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Income (Loss) |
|
|
|
|
|
|
|
|
|
|
|
|
Specialty Nutrition Systems |
$ 23.0 |
|
$ 18.6 |
|
23.7 % |
|
$ 62.1 |
|
$ 55.8 |
|
11.3 % |
|
Pain Management & Recovery |
2.0 |
|
0.8 |
|
N.M. |
|
4.0 |
|
(1.2) |
|
N.M. |
|
Corporate and Other(a) |
(24.9) |
|
(7.4) |
|
N.M. |
|
(130.2) |
|
(32.3) |
|
N.M. |
|
Total Operating Income (Loss) |
$ 0.1 |
|
$ 12.0 |
|
N.M. |
|
$ (64.1) |
|
$ 22.3 |
|
N.M. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales - percentage change (QTD) |
|
|
Total |
|
Volume |
|
Pricing/Mix |
|
Currency |
|
Other(b) |
|
Specialty Nutrition Systems |
|
|
16.1 % |
|
14.0 % |
|
0.5 % |
|
1.5 % |
|
0.1 % |
|
Pain Management & Recovery |
|
|
2.1 % |
|
2.0 % |
|
0.4 % |
|
0.9 % |
|
(1.2) % |
|
Corporate and Other |
|
|
(66.7) % |
|
(6.1) % |
|
(6.8) % |
|
— % |
|
(53.8) % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales - percentage change (YTD) |
|
|
Total |
|
Volume |
|
Pricing/Mix |
|
Currency |
|
Other(b) |
|
Specialty Nutrition Systems |
|
|
9.4 % |
|
9.1 % |
|
0.4 % |
|
0.3 % |
|
(0.4) % |
|
Pain Management & Recovery |
|
|
1.6 % |
|
2.4 % |
|
0.3 % |
|
0.2 % |
|
(1.3) % |
|
Corporate and Other |
|
|
(40.6) % |
|
(10.3) % |
|
(15.0) % |
|
(0.1) % |
|
(15.2) % |
|
______________________________ |
|
|
N.M.: Not Meaningful |
|
|
(a) |
Corporate and Other operating loss for the nine months ended September 30, 2025 includes |
|
(b) |
Other includes the effects of our withdrawal from certain revenue streams that did not meet our return criteria and rounding. |
View original content to download multimedia:https://www.prnewswire.com/news-releases/avanos-medical-inc-announces-third-quarter-2025-results-302605099.html
SOURCE Avanos Medical
FAQ
What were Avanos (AVNS) Q3 2025 revenue and net income results?
How did Avanos' Specialty Nutrition Systems (SNS) perform in Q3 2025?
What guidance did Avanos (AVNS) give for full‑year 2025 on Nov 5, 2025?
What acquisitions or divestitures did Avanos announce in 2025?
How did the goodwill impairment affect Avanos' 2025 results?
What is Avanos' cash and net debt position as of Sept 30, 2025?
